{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T12:44:15Z","timestamp":1792327455561,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"DOI":"10.1007\/s13318-026-01042-w","type":"journal-article","created":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T12:14:32Z","timestamp":1792325672000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PBPK Modeling of Varenicline: Relating Variable Pharmacokinetics to Genomics"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2043-1492","authenticated-orcid":false,"given":"Sanskruti","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3873-0899","authenticated-orcid":false,"given":"Ian S.","family":"Haworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,18]]},"reference":[{"key":"1042_CR1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.15585\/mmwr.mm7329a1","volume":"73","author":"B VanFrank","year":"2022","unstructured":"VanFrank B, Malarcher A, Cornelius ME, Schecter A, Jamal A, Tynan M. Adult smoking cessation\u2014United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;73:633\u201341. https:\/\/doi.org\/10.15585\/mmwr.mm7329a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1042_CR2","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.amjmed.2008.01.016","volume":"121","author":"M Nides","year":"2008","unstructured":"Nides M. Update on pharmacologic options for smoking cessation treatment. Am J Med. 2008;121:S20-31. https:\/\/doi.org\/10.1016\/j.amjmed.2008.01.016.","journal-title":"Am J Med"},{"key":"1042_CR3","unstructured":"Singh D, Saadabadi A. Varenicline (Updated 2024 Oct 5). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.\nhttps:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534846\/"},{"key":"1042_CR4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_218_22","volume":"65","author":"AR Patel","year":"2023","unstructured":"Patel AR, Panchal JR, Desai CK. Efficacy of varenicline versus bupropion for smoking cessation: a systematic review and meta-analysis of randomized controlled trials. Indian J Psychiatry. 2023;65:526\u201333. https:\/\/doi.org\/10.4103\/indianjpsychiatry.indianjpsychiatry_218_22.","journal-title":"Indian J Psychiatry"},{"key":"1042_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1021\/je200405w","volume":"57","author":"G Unal","year":"2012","unstructured":"Unal G, Yeloglu I, An\u0131lanmert B, Narin \u0130. pKa constant of varenicline. J Chem Eng Data. 2012;57:14\u20137. https:\/\/doi.org\/10.1021\/je200405w.","journal-title":"J Chem Eng Data"},{"key":"1042_CR6","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5414\/cpp47246","volume":"47","author":"Y Xiao","year":"2009","unstructured":"Xiao Y, Lv Y, Zhang X, Guo Y, Bergstrom T. The pharmacokinetic and tolerability profile of varenicline in healthy Chinese volunteers. Int J Clin Pharmacol Ther. 2009;47:246\u201354. https:\/\/doi.org\/10.5414\/cpp47246.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1042_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1124\/dmd.105.006767","volume":"34","author":"RS Obach","year":"2006","unstructured":"Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O\u2019Connell TN, Zandi KS, et al. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006;34:121\u201330. https:\/\/doi.org\/10.1124\/dmd.105.006767.","journal-title":"Drug Metab Dispos"},{"key":"1042_CR8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2165\/11537850-000000000-00000","volume":"49","author":"HM Faessel","year":"2010","unstructured":"Faessel HM, Obach RS, Rollema H, Ravva P, Williams KE, Burstein AH. A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokinet. 2010;49:799\u2013816. https:\/\/doi.org\/10.2165\/11537850-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"1042_CR9","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.mayocp.2013.08.015","volume":"88","author":"CA Jim\u00e9nez-Ruiz","year":"2013","unstructured":"Jim\u00e9nez-Ruiz CA, Barrios M, Pe\u00f1a S, Cicero A, Mayayo M, Crist\u00f3bal M, et al. Increasing the dose of varenicline in patients who do not respond to the standard dose. Mayo Clin Proc. 2013;88:1443\u20135. https:\/\/doi.org\/10.1016\/j.mayocp.2013.08.015.","journal-title":"Mayo Clin Proc"},{"key":"1042_CR10","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.2147\/DDDT.S178456","volume":"12","author":"SS Kwak","year":"2018","unstructured":"Kwak SS, Lee ES, Yoon HY, Kim CH, Goo YT, Kang MJ, et al. Immediate release tablet formulation of varenicline salicylate and comparative pharmacokinetic study in human volunteers. Drug Des Devel Ther. 2018;12:3377\u201392. https:\/\/doi.org\/10.2147\/DDDT.S178456.","journal-title":"Drug Des Devel Ther"},{"key":"1042_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-11-15","volume":"11","author":"LK Leung","year":"2011","unstructured":"Leung LK, Patafio FM, Rosser WW. Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysis. BMC Clin Pharmacol. 2011;11:15. https:\/\/doi.org\/10.1186\/1472-6904-11-15.","journal-title":"BMC Clin Pharmacol"},{"key":"1042_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s43586-021-00056-9","volume":"1","author":"E Uffelmann","year":"2021","unstructured":"Uffelmann E, Huang QQ, Munung NS, de Vries J, Okada Y, Martin AR, et al. Genome-wide association studies. Nat Rev Methods Primers. 2021;1:59. https:\/\/doi.org\/10.1038\/s43586-021-00056-9.","journal-title":"Nat Rev Methods Primers"},{"key":"1042_CR13","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1093\/ntr\/ntab044","volume":"23","author":"MJ Chenoweth","year":"2021","unstructured":"Chenoweth MJ, Lerman C, Knight J, Tyndale RF. A genome-wide association study of nausea incidence in varenicline-treated cigarette smokers. Nicotine Tob Res. 2021;23:1805\u20139. https:\/\/doi.org\/10.1093\/ntr\/ntab044.","journal-title":"Nicotine Tob Res"},{"key":"1042_CR14","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2174\/1568026043387791","volume":"4","author":"C G\u00fczey","year":"2004","unstructured":"G\u00fczey C, Spigset O. Genotyping as a tool to predict adverse drug reactions. Curr Top Med Chem. 2004;4:1411\u201321. https:\/\/doi.org\/10.2174\/1568026043387791.","journal-title":"Curr Top Med Chem"},{"key":"1042_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/s0165-6147(00)01717-x","volume":"22","author":"M Pirmohamed","year":"2001","unstructured":"Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci. 2001;22:298\u2013305. https:\/\/doi.org\/10.1016\/s0165-6147(00)01717-x.","journal-title":"Trends Pharmacol Sci"},{"key":"1042_CR16","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23m14937","volume":"85","author":"A Holck","year":"2024","unstructured":"Holck A, Asp M, Green H, Westrin \u00c5, Reis M. CYP2D6 genotyping and inhibition as predictors of adverse drug reactions in depressive disorders. J Clin Psychiatry. 2024;85:23m14937. https:\/\/doi.org\/10.4088\/JCP.23m14937.","journal-title":"J Clin Psychiatry"},{"key":"1042_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-60327-411-1_1","volume":"578","author":"BS Shastry","year":"2009","unstructured":"Shastry BS. SNPs: impact on gene function and phenotype. Methods Mol Biol. 2009;578:3\u201322. https:\/\/doi.org\/10.1007\/978-1-60327-411-1_1.","journal-title":"Methods Mol Biol"},{"key":"1042_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.910629","volume":"13","author":"X Wu","year":"2022","unstructured":"Wu X, Zhang F, Yu M, Ding F, Luo J, Liu B, et al. Semi-PBPK modeling and simulation to evaluate the local and systemic pharmacokinetics of OC-01 (Varenicline) nasal spray. Front Pharmacol. 2022;13:910629. https:\/\/doi.org\/10.3389\/fphar.2022.910629.","journal-title":"Front Pharmacol"},{"key":"1042_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/sj.clpt.6100405","volume":"83","author":"B Feng","year":"2008","unstructured":"Feng B, Obach RS, Burstein AH, Clark DJ, de Morais SM, Faessel HM. Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. Clin Pharmacol Ther. 2008;83:567\u201376. https:\/\/doi.org\/10.1038\/sj.clpt.6100405.","journal-title":"Clin Pharmacol Ther"},{"key":"1042_CR20","doi-asserted-by":"publisher","first-page":"D891","DOI":"10.1093\/nar\/gkad1049","volume":"52","author":"PW Harrison","year":"2024","unstructured":"Harrison PW, Amode MR, Austine-Orimoloye O, Azov AG, Barba M, Barnes I, et al. Ensembl 2024. Nucleic Acids Res. 2024;52:D891\u20139. https:\/\/doi.org\/10.1093\/nar\/gkad1049.","journal-title":"Nucleic Acids Res"},{"key":"1042_CR21","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1124\/dmd.118.082313","volume":"46","author":"V Kumar","year":"2018","unstructured":"Kumar V, Yin J, Billington S, Prasad B, Brown CDA, Wang J, et al. The importance of incorporating OCT2 plasma membrane expression and membrane potential in IVIVE of metformin renal secretory clearance. Drug Metab Dispos. 2018;46:1441\u20135. https:\/\/doi.org\/10.1124\/dmd.118.082313.","journal-title":"Drug Metab Dispos"},{"key":"1042_CR22","doi-asserted-by":"publisher","first-page":"F1669","DOI":"10.1152\/ajprenal.00422.2019","volume":"317","author":"SH Wright","year":"2019","unstructured":"Wright SH. Molecular and cellular physiology of organic cation transporter 2. Am J Physiol Renal Physiol. 2019;317:F1669\u201379. https:\/\/doi.org\/10.1152\/ajprenal.00422.2019.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1042_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/00008571-200207000-00007","volume":"12","author":"MK Leabman","year":"2002","unstructured":"Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics. 2002;12:395\u2013405. https:\/\/doi.org\/10.1097\/00008571-200207000-00007.","journal-title":"Pharmacogenetics"},{"key":"1042_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/FPC.0b013e32832cc7e9","volume":"19","author":"Y Chen","year":"2009","unstructured":"Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genom. 2009;19:497\u2013504. https:\/\/doi.org\/10.1097\/FPC.0b013e32832cc7e9.","journal-title":"Pharmacogenet Genom"},{"key":"1042_CR25","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/nar\/28.1.352","volume":"28","author":"EM Smigielski","year":"2000","unstructured":"Smigielski EM, Sirotkin K, Ward M, Sherry ST. dbSNP: a database of single nucleotide polymorphisms. Nucleic Acids Res. 2000;28:352\u20135. https:\/\/doi.org\/10.1093\/nar\/28.1.352.","journal-title":"Nucleic Acids Res"},{"key":"1042_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/genes14081609","volume":"14","author":"N Schweighofer","year":"2023","unstructured":"Schweighofer N, Strasser M, Obermayer A, Trummer O, Sourij H, Sourij C, et al. Identification of novel intronic SNPs in transporter genes associated with metformin side effects. Genes. 2023;14:1609. https:\/\/doi.org\/10.3390\/genes14081609.","journal-title":"Genes"},{"key":"1042_CR27","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1053\/j.gastro.2018.07.031","volume":"155","author":"Q Pan","year":"2018","unstructured":"Pan Q, Zhang X, Zhang L, Cheng Y, Zhao N, Li F, et al. Solute carrier organic anion transporter family member 3A1 is a bile acid efflux transporter in cholestasis. Gastroenterology. 2018;155:1578-92.e16. https:\/\/doi.org\/10.1053\/j.gastro.2018.07.031.","journal-title":"Gastroenterology"},{"key":"1042_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-025-00427-w","volume":"11","author":"P Chou","year":"2025","unstructured":"Chou P, Shannar A, Pan Y, Dave PD, Xu J, Kong AT. Application of physiologically-based pharmacokinetic (PBPK) model in drug development and in dietary phytochemicals. Curr Pharmacol Rep. 2025;11:45. https:\/\/doi.org\/10.1007\/s40495-025-00427-w.","journal-title":"Curr Pharmacol Rep"},{"key":"1042_CR29","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.apsb.2016.04.004","volume":"6","author":"X Zhuang","year":"2016","unstructured":"Zhuang X, Lu C. PBPK modeling and simulation in drug research and development. Acta Pharm Sin B. 2016;6:430\u201340. https:\/\/doi.org\/10.1016\/j.apsb.2016.04.004.","journal-title":"Acta Pharm Sin B"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01042-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01042-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01042-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T12:14:33Z","timestamp":1792325673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01042-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,18]]},"references-count":29,"alternative-id":["1042"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01042-w","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,18]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Neither of the authors have a conflict of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}